The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Nasal polyps are benign (non-cancerous) growths that develop inside the nose or sinuses. Common causes of nasal polyps include asthma, allergies, and chronic sinus infections. Nasal polyps are ...

Opens in a new tab or window The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well ...

The absorption of neffy may be affected in patients with underlying structural or anatomical nasal conditions (eg, nasal polyps, history of nasal surgery). In these patients, epinephrine products ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.

Dr. Albritton is a resident physician and Dr. Kingdom is Assistant Professor in the Department of Otolaryngology at Emory University School of Medicine, Atlanta, Ga. Albritton FD, Kingdom TT.

GSK receives Japanese MHLW approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Thursday, August 29, 2024, 09:00 Hrs [IST] GSK plc announc ...

Albritton FD, Kingdom TT. Cystic Fibrosis and Nasal Polyposis. MedGenMed 2(1), 2000 [formerly published in Medscape Pulmonary Medicine eJournal 4(1), 2000]. Available at: https://www.medscape.com ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...